No connection

Search Results

INSP vs NBTX

INSP
Inspire Medical Systems, Inc.
BULLISH
Price
$55.11
Market Cap
$1.59B
Sector
Healthcare
AI Confidence
85%
NBTX
Nanobiotix S.A.
BEARISH
Price
$31.83
Market Cap
$1.54B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
INSP
11.27
NBTX
--
Forward P/E
INSP
21.32
NBTX
439.39
P/B Ratio
INSP
2.02
NBTX
-19.23
P/S Ratio
INSP
1.74
NBTX
47.36
EV/EBITDA
INSP
20.02
NBTX
-150.9

Profitability

Gross Margin
INSP
85.39%
NBTX
100.0%
Operating Margin
INSP
17.14%
NBTX
-196.42%
Profit Margin
INSP
15.95%
NBTX
-73.52%
ROE
INSP
19.77%
NBTX
--
ROA
INSP
3.71%
NBTX
-10.06%

Growth

Revenue Growth
INSP
12.2%
NBTX
--
Earnings Growth
INSP
308.4%
NBTX
--

Financial Health

Debt/Equity
INSP
0.04
NBTX
--
Current Ratio
INSP
6.08
NBTX
1.09
Quick Ratio
INSP
4.46
NBTX
1.05

Dividends

Dividend Yield
INSP
--
NBTX
--
Payout Ratio
INSP
0.0%
NBTX
0.0%

AI Verdict

INSP BULLISH

INSP exhibits strong fundamental health with a Piotroski F-Score of 7/9 and an exceptionally clean balance sheet (Debt/Equity 0.04). While the stock has suffered a severe multi-year price collapse, it is currently trading almost exactly at its Graham Number ($54.84), suggesting it has reached a defensive valuation floor. The massive disconnect between the current price ($55.11) and the growth-based intrinsic value ($144.25), coupled with explosive earnings growth (308.4% YoY), presents a compelling value-growth opportunity. Despite bearish technicals and insider selling, the underlying profitability and liquidity metrics are superior to sector averages.

Strengths
Strong financial health indicated by Piotroski F-Score of 7/9
Exceptional gross margins (85.39%) and healthy ROE (19.77%)
Negligible debt levels (Debt/Equity 0.04) and high liquidity (Current Ratio 6.08)
Risks
Severe long-term price deterioration (5Y Change: -77.1%)
Bearish insider sentiment with recent selling activity
Strongly bearish technical trend (0/100 score)
NBTX BEARISH

NBTX exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational instability. The valuation is extreme, with a Price/Sales ratio of 47.36 and a negative Price/Book ratio (-19.23), suggesting the company is trading on speculative future catalysts rather than current assets or earnings. While the stock has seen a massive 1-year price surge of 855.9% and maintains a 'strong_buy' analyst consensus, the deterministic data reveals a company with negative equity and unsustainable margins. The disconnect between the technical momentum and the underlying financial decay presents a high-risk profile.

Strengths
Exceptional 1-year price performance (+855.9%)
Strong analyst consensus (Strong Buy)
Consistent earnings surprises (3/4 quarters beat estimates)
Risks
Critical financial health (Piotroski F-Score 2/9)
Extreme valuation (Forward P/E of 439.39 and P/S of 47.36)
Negative shareholders' equity (Price/Book of -19.23)

Compare Another Pair

INSP vs NBTX: Head-to-Head Comparison

This page compares Inspire Medical Systems, Inc. (INSP) and Nanobiotix S.A. (NBTX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile